Manali Kamdar, MD, outlines emerging treatment strategies, including CD20 bispecific antibodies, for patients with LBCL who progress after liso-cel therapy.
CU Anschutz
Anschutz Cancer Pavilion
1665 North Aurora Court
2004
Aurora, CO 80045
Kamdar Discusses Treatment Options Beyond Liso-cel for Relapsed/Refractory LBCL
by Cancer Network | December 15, 2025
